Start
november 2022

VEBIS - Vaccine effectiveness against COVID-19 and seasonal influenza in primary care

Duur: Nov 2022 - continuesly

Background

Since July 2022, the I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) network has become integrated into the VEBIS (Vaccine Effectiveness, Burden and Impact Studies) project. The network has been estimating influenza vaccine effectiveness (VE) at primary care level in the European Union (EU) and European Economic Area (EEA) since 2008–2009, using a multicentre study design including up to 12 countries.

Aim

The aim is to estimate vaccine effectiveness against COVID-19 and seasonal influenza in patients consulting primary care physicians.

Project design

The design is a multicentre test-negative case-control study. Participating practitioners collect specimens and interviewed all or a systematic sample of patients consulting for acute respiratory infection (ARI) or influenza-like illness (ILI). All specimens are PCR-tested for influenza virus, SARS-CoV-2 and other respiratory viruses.

Result

Results will be published in peer-reviewed open access articles.

Project website: Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza

Dit project wordt gesubsidieerd door
European Centre for Disease Prevention and Control (ECDC)
Projectpartners
Epiconcept, France; National Institute for Public Health and the Environment (RIVM), the Netherlands